Skip to content
Screener

CytomX Therapeutics CTMX Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$18.7MBeat by $378.0K
EPS-$0.00Beat by $0.06
Revenue estimate$18.3M
EPS estimate-$0.06

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$0.09

Financials

Q2 2025

Income statement

See full
Revenue$18.7M-25.7%
Operating income-$1.3M+84.8%
Net income-$154.0K+97.6%
EPS (diluted)-$0.00+100%

Balance sheet

See full
Cash & equivalents$49.0M+13.4%
Total debt$6.9M-41.4%
Total equity$119.9M+484%
Total assets$175.1M+9.9%

Cash flow

See full
Operating cash flow-$15.8M+19.4%
CapEx$27.0K-71.9%
Free cash flow-$15.8M+19.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$337.14M+255%
Enterprise value$294.99M+364%
P/E7×—
P/S2.4×+1.6×

Profitability

See full
Operating margin30.6%+25.8pp
Net margin34%—
FCF margin-55.1%-10.6pp

Returns & leverage

See full
Debt / equity0.1×—
Current ratio4.2×+3.2×

FAQ

When did CytomX Therapeutics report Q2 2025 earnings?
CytomX Therapeutics (CTMX) reported Q2 2025 earnings on August 7, 2025 after market close.
What were CytomX Therapeutics's Q2 2025 revenue and EPS?
CytomX Therapeutics reported revenue of $18.7M and eps of $-0.00 for Q2 2025.
Did CytomX Therapeutics beat estimates in Q2 2025?
Revenue beat the consensus estimate of $18.3M by $378.0K. EPS beat the consensus estimate of $-0.06 by $0.06.
How did CytomX Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 25.7% from $25.1M a year earlier and eps grew 98.5% from $-0.08.
Where can I find CytomX Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-105053) and the 10-Q periodic report (0000950170-25-104991) directly on SEC EDGAR. The filing index links above go to sec.gov.